2021
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka J, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021, 137: 1353-1364. PMID: 32871584, PMCID: PMC8555417, DOI: 10.1182/blood.2020006464.Peer-Reviewed Original ResearchConceptsT-cell/histiocyte-rich large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaMalignant B cellsDiffuse large B-cell lymphomaClassic Hodgkin lymphomaPD-1B cellsImmune signaturesImmune escapePD-1/PD-L1 pathwayPD-L1/PDImmune escape pathwayPD-1 blockadeImmune cell infiltratesPD-L1 expressionRefractory hematologic malignanciesPD-L1 pathwayMulti-institutional cohortClinical responsePartial responseCell infiltrateComplete responsePD-L1Aggressive variant
2020
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover S, Dougan M, Tyan K, Giobbie‐Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin‐Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis. Cancer 2020, 126: 3758-3767. PMID: 32567084, PMCID: PMC7381363, DOI: 10.1002/cncr.32966.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsVitamin D useVitamin D intakeICI colitisD intakeD useDiscovery cohortDevelopment of ICIsImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisCombination immune checkpoint inhibitorsMultivariable logistic regression analysisDana-Farber Cancer InstituteRisk of colitisMultivariable regression analysisLogistic regression analysisMassachusetts General HospitalRegression analysisCheckpoint inhibitorsLaboratory characteristicsPD-1Ulcerative colitisLymphocyte ratioMelanoma patientsVitamin DAssociation of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.
Tyan K, Grover S, Dougan M, Sullivan R, Giobbie-Hurder A, Blum S, Ishizuka J, Qazi T, Elias R, Vora K, Ruan A, Martin-Doyle W, Eastman L, Davis M, Gargano M, Haq R, Buchbinder E, Ott P, Hodi F, Rahma O. Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.5_suppl.89.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeutrophil/lymphocyte ratioVitamin D useVitamin D intakeICI colitisD intakeD useDiscovery cohortDevelopment of ICIsImmune checkpoint inhibitor-induced colitisPretreatment Neutrophil/Lymphocyte RatioCheckpoint inhibitor-induced colitisDana-Farber Cancer InstituteMultivariate logistic regression analysisRisk of colitisMultivariable regression analysisLogistic regression analysisMassachusetts General HospitalRegression analysisCheckpoint inhibitorsLaboratory characteristicsPD-1Ulcerative colitisLymphocyte ratioMelanoma patients
2019
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019, 20: 326-336. PMID: 30778252, PMCID: PMC6673650, DOI: 10.1038/s41590-019-0312-6.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesExhausted tumor-infiltrating lymphocytesT cell dysfunctionExhausted CD8T cellsCheckpoint blockadeCell dysfunctionAnti-PD-1 therapyInhibitory receptor PD-1Chronic viral infectionsExhausted T cellsReceptor PD-1Checkpoint blockade therapyDysfunctional CD8PD-1Antibody blockadeTumor controlSuch therapyCD8Viral infectionTumor growthExhausted cellsSpecific subpopulationsBlockadeTherapy